MESO

Mesoblast (MESO)

About Mesoblast (MESO)

Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. Its medicines target cardiovascular diseases, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases. The company was founded by Silviu Itescu on June 8, 2004 and is headquartered in Melbourne, Australia.

Details

Daily high

$16.07

Daily low

$15.55

Price at open

$15.74

52 Week High

$21.50

52 Week Low

$9.61

Market cap

2.1B

Dividend yield

0.00%

Volume

283,979

Avg. volume

222,159

P/E ratio

-18.86

Mesoblast News